We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Eddy Ben-Ami, Founder and CEO at NeuraLight! NeuraLight is tackling one of neurology’s biggest problems: how crudely we measure disease progression in conditions like Parkinson’s, MS, ALS, and Huntington’s. Despite MRI and gene sequencing, the current “gold standard” is pushing patients to test balance, or asking caregivers how hard it is to adjust clothes in bed. Ben-Ami explains how NeuraLight replaces this with a 10‑minute, tablet-based eye-movement test using a standard camera. By leveraging decades of visual-system research (largely from primate studies), they extract functional biomarkers tied to specific neural pathways and brain regions. The result: objective, quantitative measures of brain function that are highly sensitive to change over time. Over the past four years, NeuraLight has run large longitudinal studies on thousands of patients across multiple neurodegenerative diseases. In Parkinson’s, they’ve shown their metrics are 10x more sensitive to change than the existing clinical gold standard, with results being presented at ADPD in Copenhagen alongside the inventors of that standard. Commercially, NeuraLight is already being paid as a per-test diagnostic in five pharma drug trials (Phase 1 and 2), where their measures serve as secondary/exploratory endpoints. Their moat is a growing, hard-to-replicate dataset linking eye movements to rich clinical data. Looking ahead to 2026, they’re focused on successful readouts from ongoing trials, expanding into psychiatry, and bringing their technology into preventative-care platforms so even healthy people can track brain function—before catastrophe strikes. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your journey. What does NeuraLight do? You do a lot of work with neurodegenerative diseases – Parkinson’s, MS, ALS, and Huntington’s, specifically – where are you holding right now in terms of product development? What is your value creation? In these drug trials, are you the primary endpoint or a secondary endpoint where they’re collecting an additional CRF together with their primary endpoint? The primary endpoint is the gold standard, and no one will talk to you until you can show that you’re at least as good as the gold standard. So, at the end of the trial, have you thought about taking the data and doing a retrospective analysis to see how well your exploratory endpoint correlates with the primary endpoint? Can you piggyback on these trials to use the data to validate your measures? What is your business model? How do you capture value from this? What’s your moat? What prevents someone from doing the same thing you’re doing? What are three things you want to do for your customers in 2026? Do you need a 510(k) from the FDA to clear these diagnostics? What is the biggest anti-pattern in your industry? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube. Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!
